JENA, Germany--(BUSINESS WIRE)-- eZono AG (“eZono”), a private corporation that designs, develops and distributes state of the art tablet ultrasound systems, today announced a leadership transition that will accelerate the company’s growth. eZono’s supervisory board has appointed Graham D. Cox as the company’s Chief Executive Officer effective 1st June 2013. Mr. Cox will succeed Allan R. Dunbar, co-founder and acting CEO of eZono, who remains with the company as Chief Commercial Officer.
“We are very excited that Graham is bringing his skill, experience and remarkable track record to eZono. I firmly believe that, together with Allan and the team, he will enable the company to realise its enormous potential” said Hugo Harrod of MVM Life Science Partners, lead investor in eZono.
“Graham is the best candidate for eZono CEO in the world. I’m really happy he will join so we can bring the benefits of our innovative solutions, such as eZono’s groundbreaking needle guidance, to more clinicians and patients across the globe” commented Allan Dunbar.
“eZono has an impressive and unique team with a proven ability to innovate in the field of portable ultrasound. I am very excited to join the company and take these innovations to market worldwide” added Graham Cox.
Mr. Cox is an ultrasound industry veteran with more than 35 years of experience in the field. He joins eZono from SonoSite, a recognised leader in point-of-care ultrasound. At SonoSite, he served as Senior Vice President, Worldwide Sales & Distribution. During his 13 year tenure, annual revenues grew from zero to over $250 Million. Prior to joining SonoSite, Mr. Cox also held senior positions running sales and distribution for ATL Ultrasound (now Philips Medical Systems) and Acuson (now Siemens AG). Mr. Cox received an electronic engineer education and holds an Executive MBA (Hon) from the International Management Centers Association.
About eZono
eZono AG headquartered in Jena, Germany, designs, develops and distributes state of the art tablet ultrasound systems specifically targeted at point-of-care markets. The first generation eZono 3000 is CE marked and achieved FDA clearance in July 2011 and is now being successfully marketed and sold globally. The company is dedicated to supplying sophisticated imaging solutions to empower point-of-care providers.
Contact:
eZono
André Jäkel
+ 49 364 1876 1730
press@ezono.com
Help employers find you! Check out all the jobs and post your resume.
